Dubious Research, The Lancet, 2011:

Does simvastatin prevent heart disease in at-risk patients if you combine it with magic spells, blood letting or ezetimibe?

A recent study, published in The Lancet, shows that kidney disease patients have fewer cardiovascular events if they take Vytorin than placebo. We already learned from the 4S study many decades ago that simvastatin lowers heart attack risk. So what do we learn from a study that compares simvastatin plus something else with placebo?

Nothing. Or am I missing something here?

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial : The Lancet.